Sichenzia Ross Ference LLP Represents Zynex, Inc. and Selling Shareholder in $55 Million Public Offering of Common Stock
Press Release – New York, NY – July 17, 2020 – Sichenzia Ross Ference LLP today announced that it represented Zynex, Inc. (NASDAQ: “ZYXI”), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, and a certain shareholder in a public offering of an aggregate of 2,500,000 shares of its common stock at a public offering price of $22.00 per share. The offering was made pursuant to a registration statement on Form S-3 (File No. 333-230128) that was filed with the Securities and Exchange Commission (the “SEC”) and became effective on March 12, 2019, and a registration statement on Form S-3 (File No. 333-232367) that was filed with the SEC and became effective on July 3, 2019, for the shares of common stock being offered by ZYXI and the selling stockholder, respectively.
Piper Sandler & Co. acted as sole book-running manager for the offering. B. Riley FBR, Inc., Ladenburg Thalmann & Co. Inc., H.C. Wainwright & Co. and Northland Capital Markets acted as co-managers.
The Sichenzia Ross Ference LLP team was led by partners Gregory Sichenzia, Jay Yamamoto, and David Manno and associate Yian Pan.
- Sichenzia Ross Ference LLP Announces Over 80 Capital Markets Transactions Valued Over $2 Billion at the Closing of 2021 - January 13, 2022
- Sichenzia Ross Ference LLP Adds Two Key Additions to its Corporate and Securities Law Team - January 11, 2022
- Sichenzia Ross Ference LLP Represents Aegis Capital Corp. in $9.8 Million Underwritten Offering of BiondVax Pharmaceuticals Ltd. - December 30, 2021